Logo image of RGLS

REGULUS THERAPEUTICS INC (RGLS) Stock Fundamental Analysis

NASDAQ:RGLS - Nasdaq - US75915K3095 - Common Stock - Currency: USD

8.16  +0.02 (+0.25%)

After market: 8.02 -0.14 (-1.72%)

Fundamental Rating

3

Taking everything into account, RGLS scores 3 out of 10 in our fundamental rating. RGLS was compared to 556 industry peers in the Biotechnology industry. RGLS has a great financial health rating, but its profitability evaluates not so good. RGLS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year RGLS has reported negative net income.
In the past year RGLS has reported a negative cash flow from operations.
In the past 5 years RGLS always reported negative net income.
In the past 5 years RGLS always reported negative operating cash flow.
RGLS Yearly Net Income VS EBIT VS OCF VS FCFRGLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of RGLS (-63.51%) is worse than 61.22% of its industry peers.
Looking at the Return On Equity, with a value of -68.85%, RGLS is in line with its industry, outperforming 55.83% of the companies in the same industry.
Industry RankSector Rank
ROA -63.51%
ROE -68.85%
ROIC N/A
ROA(3y)-71.13%
ROA(5y)-59.17%
ROE(3y)-95.84%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
RGLS Yearly ROA, ROE, ROICRGLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RGLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RGLS Yearly Profit, Operating, Gross MarginsRGLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, RGLS has more shares outstanding
RGLS has more shares outstanding than it did 5 years ago.
RGLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RGLS Yearly Shares OutstandingRGLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RGLS Yearly Total Debt VS Total AssetsRGLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 46.61 indicates that RGLS is not in any danger for bankruptcy at the moment.
RGLS has a Altman-Z score of 46.61. This is amongst the best in the industry. RGLS outperforms 98.03% of its industry peers.
RGLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 46.61
ROIC/WACCN/A
WACCN/A
RGLS Yearly LT Debt VS Equity VS FCFRGLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

RGLS has a Current Ratio of 16.31. This indicates that RGLS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 16.31, RGLS belongs to the top of the industry, outperforming 89.59% of the companies in the same industry.
A Quick Ratio of 16.31 indicates that RGLS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 16.31, RGLS belongs to the top of the industry, outperforming 89.59% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.31
Quick Ratio 16.31
RGLS Yearly Current Assets VS Current LiabilitesRGLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1

3. Growth

3.1 Past

RGLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RGLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.01% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.52%
EPS Next 2Y-11.37%
EPS Next 3Y22.97%
EPS Next 5Y47.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RGLS Yearly Revenue VS EstimatesRGLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
RGLS Yearly EPS VS EstimatesRGLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

1

4. Valuation

4.1 Price/Earnings Ratio

RGLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGLS Price Earnings VS Forward Price EarningsRGLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGLS Per share dataRGLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as RGLS's earnings are expected to grow with 22.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.37%
EPS Next 3Y22.97%

0

5. Dividend

5.1 Amount

RGLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

REGULUS THERAPEUTICS INC

NASDAQ:RGLS (6/24/2025, 8:00:02 PM)

After market: 8.02 -0.14 (-1.72%)

8.16

+0.02 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners82.87%
Inst Owner Change-0.25%
Ins Owners2.8%
Ins Owner Change-8.1%
Market Cap564.92M
Analysts73.33
Price Target8.67 (6.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.3%
Min EPS beat(2)6.63%
Max EPS beat(2)39.98%
EPS beat(4)2
Avg EPS beat(4)2.97%
Min EPS beat(4)-21.11%
Max EPS beat(4)39.98%
EPS beat(8)5
Avg EPS beat(8)-0.32%
EPS beat(12)7
Avg EPS beat(12)2.1%
EPS beat(16)9
Avg EPS beat(16)0.36%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.41%
PT rev (3m)-27.97%
EPS NQ rev (1m)1.85%
EPS NQ rev (3m)12.4%
EPS NY rev (1m)23.3%
EPS NY rev (3m)11.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.18
P/tB 8.19
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS1
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -63.51%
ROE -68.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.13%
ROA(5y)-59.17%
ROE(3y)-95.84%
ROE(5y)-79.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.31
Quick Ratio 16.31
Altman-Z 46.61
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)221.31%
Cap/Depr(5y)143.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.28%
EPS Next Y-5.52%
EPS Next 2Y-11.37%
EPS Next 3Y22.97%
EPS Next 5Y47.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.74%
OCF growth 3YN/A
OCF growth 5YN/A